Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 15/20 | 0.59 |
| ▸ | NOS3 | P29474 | 11/20 | 0.59 |
| ▸ | NOS2 | P35228 | 7/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7073206 | 0.93 | NOS1 (0.60) | NOS1NOS3NOS2 | |
| SCHEMBL419682 | 0.90 | NOS1 (0.57) | NOS1NOS3NOS2 | |
| SCHEMBL8275579 | 0.88 | NOS1 (0.44) | NOS1NOS3NOS2CYP1A1CYP1B1 | |
| SCHEMBL8275628 | 0.87 | NOS1 (0.54) | NOS1NOS3NOS2JAK2JAK1 | |
| SCHEMBL5080969 | 0.86 | NOS1 (0.60) | NOS1NOS3NOS2 | |
| SCHEMBL422030 | 0.84 | NOS1 (0.58) | NOS1NOS3NOS2 | |
| SCHEMBL8471365 | 0.84 | NOS1 (0.51) | NOS1NOS3NOS2SUV39H2 | |
| SCHEMBL421876 | 0.82 | NOS1 (0.57) | NOS1NOS3NOS2 | |
| SCHEMBL422133 | 0.81 | NOS1 (0.66) | NOS1NOS3NOS2SLC6A4HTR6 | |
| SCHEMBL424370 | 0.80 | NOS1 (0.54) | NOS1NOS3NOS2CYP1A1CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032847-A1 | 2-amino-6(2,4,5-substitued-phenyl)-pyridines | PFIZER INC. | 2005-02-10 | — | — | US | claimed |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | claimed |
| US-6803470-B2 | NITRIC OXIDE SYNTHASE INHIBITORS. | PFIZER INC | 2004-10-12 | — | — | US | claimed |
| EP-1434624-A1 | 2-AMINO-6-(2,4,5-SUBSTITUTED-PHENYL)-PYRIDINES FOR USE AS NITRIC OXIDE SYNTHASE INHIBITORS | Pfizer Products Inc. (US) | 2004-07-07 | — | — | EP | claimed |
| JP-2003523941-A | — | — | 2003-08-12 | — | — | JP | claimed |
| US-20030087891-A1 | 2-Amino-6-(2,4,5-substituted-phenyl)-pyridines | PFIZER INC. | 2003-05-08 | — | — | US | claimed |
| WO-2003030993-A1 | 2-AMINO-6-(2,4,5-SUBSTITUTED-PHENYL)-PYRIDINES FOR USE AS NITRIC OXIDE SYNTHASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-04-17 | — | — | WO | claimed |
| EP-1178784-A1 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2002-02-13 | — | — | EP | claimed |
| WO-2000071107-A2 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | claimed |
| US-20080070952-A1 | Inhibition or Treatment of Dyskinesia | PROXIMAGEN LTD., (GB) | 2008-03-20 | — | — | US | disclosed |
| US-20080070952-A1 | Inhibition or Treatment of Dyskinesia | PROXIMAGEN LTD., (GB) | 2008-03-20 | — | — | US | disclosed |
| US-20080070952-A1 | Inhibition or Treatment of Dyskinesia | PROXIMAGEN LTD., (GB) | 2008-03-20 | — | — | US | disclosed |
| EP-1850838-A2 | INHIBITION OR TREATMENT OF DYSKINESIA | Proximagen Ltd. (GB) | 2007-11-07 | — | — | EP | disclosed |
| EP-1434624-B1 | 2-AMINO-6-(2,4,5-SUBSTITUTED-PHENYL)-PYRIDINES FOR USE AS NITRIC OXIDE SYNTHASE INHIBITORS | PFIZER PROD INC (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20030087891-A1 | 2-Amino-6-(2,4,5-substituted-phenyl)-pyridines | PFIZER INC. | 2003-05-08 | — | — | US | disclosed |
| WO-2003030993-A1 | 2-AMINO-6-(2,4,5-SUBSTITUTED-PHENYL)-PYRIDINES FOR USE AS NITRIC OXIDE SYNTHASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-04-17 | — | — | WO | disclosed |
| WO-2003030993-A1 | 2-AMINO-6-(2,4,5-SUBSTITUTED-PHENYL)-PYRIDINES FOR USE AS NITRIC OXIDE SYNTHASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-04-17 | — | — | WO | disclosed |
| WO-2003030993-A1 | 2-AMINO-6-(2,4,5-SUBSTITUTED-PHENYL)-PYRIDINES FOR USE AS NITRIC OXIDE SYNTHASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-04-17 | — | — | WO | disclosed |
| EP-1178784-A1 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000071107-A2 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070952-A1 | Inhibition or Treatment of Dyskinesia | DBH, COMT, DDO | NOS1 15/4885NOS3 18/4885NOS2 29/4885 |
| US-20030087891-A1 | 2-Amino-6-(2,4,5-substituted-phenyl)-pyridines | PNMT, HTR6, HTR2C | NOS1 2251/4885NOS3 1089/4885NOS2 1257/4885 |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | NOS1, NOS3, NPBWR1 | NOS1 1/4885NOS3 2/4885NOS2 6/4885 |
| US-20050032847-A1 | 2-amino-6(2,4,5-substitued-phenyl)-pyridines | PNMT, HTR6, HTR2C | NOS1 2336/4885NOS3 1069/4885NOS2 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.